Dietary nitrite supplementation attenuates cardiac remodeling in l-NAME-induced hypertensive rats

Nitric Oxide. 2017 Jul 1:67:1-9. doi: 10.1016/j.niox.2017.04.009. Epub 2017 Apr 21.

Abstract

Loss of nitric oxide (NO) bioavailability underlies the development of hypertensive heart disease. We investigated the effects of dietary nitrite on NG-nitro-l-arginine methyl ester (l-NAME)-induced hypertension. Sprague-Dawley rats were divided into five groups: an untreated control group, an l-NAME-treated group, and three other l-NAME-treated groups supplemented with 10 mg/L or 100 mg/L of nitrite or 100 mg/L of captopril in drinking water. After the 8-week experimental period, mean arterial blood pressure was measured, followed by sampling of blood and heart tissue for assessment of nitrite/nitrate levels in the plasma and heart, the plasma level of angiotensin II (AT II), and the heart transcriptional levels of AT II type 1 receptor (AT1R), transforming growth factor-β1 (TGF-β1), and connective tissue proteins such as type 1 collagen and fibronectin. Heart tissue was analyzed by histopathological morphometry, including assessments of ventricular and coronary vascular hypertrophy and fibrosis, as well as immunohistochemistry analyses of myocardial expression of AT1R. l-NAME treatment reduced the plasma nitrate level and led to the development of hypertension, with increased plasma levels of AT II and increased heart transcriptional levels of AT1R and TGF-β1-mediated connective tissue proteins, showing myocardial and coronary arteriolar hypertrophy and fibrosis. However, dietary nitrite supplementation inhibited TGF-β1-mediated cardiac remodeling by suppressing AT II and AT1R. These results suggest that dietary nitrite levels achievable via a daily high-vegetable diet could improve hypertensive heart disease by inhibiting AT II-AT1R-mediated cardiac remodeling.

Keywords: Angiotensin II; Angiotensin II type 1 receptor; Hypertension; Nitrite; l-NAME.

MeSH terms

  • Angiotensin II / blood
  • Angiotensin II / metabolism
  • Animals
  • Antihypertensive Agents / administration & dosage
  • Antihypertensive Agents / blood
  • Antihypertensive Agents / therapeutic use
  • Captopril / therapeutic use
  • Cardiomegaly / chemically induced
  • Cardiomegaly / drug therapy
  • Collagen Type I / genetics
  • Collagen Type I / metabolism
  • Coronary Vessels / pathology
  • Dietary Supplements*
  • Fibronectins / genetics
  • Fibronectins / metabolism
  • Fibrosis / drug therapy
  • Heart Ventricles / pathology
  • Hypertension / chemically induced*
  • Male
  • Myocardium / pathology
  • NG-Nitroarginine Methyl Ester / adverse effects*
  • Nitrates / blood
  • Nitrites / administration & dosage
  • Nitrites / blood
  • Nitrites / therapeutic use*
  • RNA / genetics
  • RNA / metabolism
  • Rats, Sprague-Dawley
  • Receptor, Angiotensin, Type 1 / metabolism
  • Transforming Growth Factor beta / genetics
  • Transforming Growth Factor beta / metabolism
  • Ventricular Remodeling / drug effects*

Substances

  • Antihypertensive Agents
  • Collagen Type I
  • Fibronectins
  • Nitrates
  • Nitrites
  • Receptor, Angiotensin, Type 1
  • Transforming Growth Factor beta
  • Angiotensin II
  • RNA
  • Captopril
  • NG-Nitroarginine Methyl Ester